Cargando…

The Relationship between Urotensin II and its Receptor and the Clinicopathological Parameters of Breast Cancer

BACKGROUND: Urotensin II is a vasoactive polypeptide. It is known that some vasoactive polypeptides are produced and secreted by tumor cells, and act as a paracrine growth stimulant. The aim of this study was to examine the relationship between urotensin II and its receptor’s messenger RNA expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balakan, Ozan, Kalender, Mehmet Emin, Suner, Ali, Cengiz, Beyhan, Oztuzcu, Serdar, Bayraktar, Recep, Borazan, Ersin, Babacan, Taner, Camci, Celaletdin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2014
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138065/ https://www.ncbi.nlm.nih.gov/pubmed/25112588 http://dx.doi.org/10.12659/MSM.890459

Ejemplares similares

Polymorphisms in the MTHFR gene are associated with recurrence risk in lymph node-positive breast cancer patients
por: Suner, Ali, et al.
Publicado: (2016)

Importance of HER2 Work-Up and Treatment Even in Patients with Poor Performance Status: A Case Report
por: Suner, Ali, et al.
Publicado: (2014)

Prognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib
por: Kus, Tulay, et al.
Publicado: (2015)

Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel
por: Kus, Tulay, et al.
Publicado: (2016)

Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?
por: Kus, Tulay, et al.
Publicado: (2015)

Collision tumor consisting of primary follicular lymphoma and adenocarcinoma in the cecum: A case report and literature review
por: KUS, TULAY, et al.
Publicado: (2016)

Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study
por: Aktas, Gokmen, et al.
Publicado: (2016)

Assessment of expressions of Bcl-XL, b-FGF, Bmp-2, Caspase-3, PDGFR-α, Smad1 and TGF-β1 genes in a rat model of lung ischemia/reperfusion
por: Şimşek, Hasan, et al.
Publicado: (2016)

Effects of Thymoquinone on Urotensin-II and TGF-β1 Levels in Model of Osteonecrosis in Rats
por: Yilmaz, Mehmet, et al.
Publicado: (2023)

Cetuximab-induced esophageal ulcer: the first report in literature
por: Babacan, Taner, et al.
Publicado: (2014)

Role of Urotensin-II in Saphenous Vein Graft Disease
por: Tüysüz, Mehmet Erin, et al.
Publicado: (2020)

Urotensin II in cardiovascular regulation
por: Russell, Fraser D
Publicado: (2008)

The distribution of circulating microRNA and their relation to coronary disease
por: Freedman, Jane E, et al.
Publicado: (2012)

Central and Peripheral Effects of Urotensin II and Urotensin II-Related Peptides on Cardiac Baroreflex Sensitivity in Trout
por: Lancien, Frédéric, et al.
Publicado: (2017)

The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes family
por: Ulasli, Mustafa, et al.
Publicado: (2014)

Inhibitory Effect of an Urotensin II Receptor Antagonist on Proinflammatory Activation Induced by Urotensin II in Human Vascular Endothelial Cells
por: Park, Sung Lyea, et al.
Publicado: (2013)

Divergent cardio-ventilatory and locomotor effects of centrally and peripherally administered urotensin II and urotensin II-related peptides in trout
por: Vanegas, Gilmer, et al.
Publicado: (2015)

Urotensin II levels in patients with chronic kidney disease and kidney transplants
por: Hursitoglu, Mehmet, et al.
Publicado: (2012)

An Unusual Case of Aplastic Anemia Caused by Temozolomide
por: Comez, Gazi, et al.
Publicado: (2010)

Potential Clinical Implications of the Urotensin II Receptor Antagonists
por: Tsoukas, Philip, et al.
Publicado: (2011)

Urotensin II Promotes Atherosclerosis in Cholesterol-Fed Rabbits
por: Li, Yafeng, et al.
Publicado: (2014)

Urotensin-II: More Than a Mediator for Kidney
por: Balat, Ayşe, et al.
Publicado: (2012)

Blockade of Urotensin II Receptor Prevents Vascular Dysfunction
por: Kim, Young-Ae, et al.
Publicado: (2016)

Urotensin II levels in patients with inflammatory bowel disease
por: Alicic, Damir, et al.
Publicado: (2021)

Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures
por: Merlino, Francesco, et al.
Publicado: (2013)

A closer look at the role of urotensin II in the metabolic syndrome
por: Barrette, Pierre-Olivier, et al.
Publicado: (2012)

Urotensin II in Invertebrates: From Structure to Function in Aplysia californica
por: Romanova, Elena V., et al.
Publicado: (2012)

Irisin levels are associated with urotensin II levels in diabetic patients
por: He, Wan-Yu, et al.
Publicado: (2015)

Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma
por: Portnoy, Alison, et al.
Publicado: (2013)

The Role of Urotensin-II in Obesity and Metabolic Syndrome in Pediatric Population
por: Simunovic, Marko, et al.
Publicado: (2022)

Urotensin II level is elevated in inflammatory bowel disease patients
por: Zhang, Yan, et al.
Publicado: (2022)

Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction
por: Ogawa, Akiko, et al.
Publicado: (2023)

Association Analysis of Urotensin II Gene (UTS2) and Flanking Regions with Biochemical Parameters Related to Insulin Resistance
por: Sáez, María E., et al.
Publicado: (2011)

Urotensin 2 and Oxidative Stress Levels in Maternal Serum in Pregnancies Complicated by Intrauterine Growth Restriction
por: Celik, Esra, et al.
Publicado: (2019)

Urotensin-II and endothelin-I levels after contrast media administration in patients undergoing percutaneous coronary interventions
por: Ulas, Turgay, et al.
Publicado: (2013)

miR-132 and miR-942 Expression Levels in Children with Attention Deficit and Hyperactivity Disorder: A Controlled Study
por: Coskun, Seyma, et al.
Publicado: (2021)

The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats
por: ZHAO, JUAN, et al.
Publicado: (2013)

Urotensin-II System in Genetic Control of Blood Pressure and Renal Function
por: Debiec, Radoslaw, et al.
Publicado: (2013)

The Urotensin II System and Carotid Atherosclerosis: A Role in Vascular Calcification
por: Albanese, Isabella, et al.
Publicado: (2016)

Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma
por: Liu, Dian-Gang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5lba00j36rrr80iletlaoqr4ph